Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's specific circumstances and the latest available evidence. Dosages and guidelines may vary and require verification with current prescribing information and local regulations.

Urticaria

Overview

• Definition: Urticaria, commonly known as hives, is a skin condition characterized by the transient appearance of intensely pruritic (itchy), erythematous (red), raised wheals (hives) that typically blanch with pressure. Individual wheals usually resolve spontaneously within 24 hours without leaving residual marks. Angioedema, a deeper swelling involving the dermis and subcutaneous tissues, may occur concomitantly or in isolation.
• Epidemiology:
  • Lifetime prevalence: Approximately 15-25% of the general population will experience urticaria at least once in their lifetime.
  • Chronic Urticaria (CU): Affects about 0.5-1% of the population.
  • Age: Can occur at any age, but most common in young to middle-aged adults (20-40 years). Chronic spontaneous urticaria (CSU) is more common in women.
  • Sex: Female preponderance in chronic forms, particularly CSU (ratio 2:1).
• Classification:
  • Acute Urticaria (AU): Urticaria with a duration of less than 6 weeks. Often triggered by infections, medications, foods, or insect stings.
  • Chronic Urticaria (CU): Urticaria persisting for 6 weeks or longer, with daily or almost daily occurrence. CU is further classified into:
    • Chronic Spontaneous Urticaria (CSU): Previously known as chronic idiopathic urticaria. Urticaria occurs without an identifiable external trigger.
    • Chronic Inducible Urticaria (CIndU): Urticaria is recurrently induced by specific physical or environmental stimuli. Examples include:
      • Dermographism (urticaria factitia)
      • Cold urticaria
      • Delayed pressure urticaria
      • Heat urticaria
      • Solar urticaria
      • Vibratory angioedema
      • Cholinergic urticaria
      • Contact urticaria
      • Aquagenic urticaria

Pathophysiology

• Mechanism: Urticaria is primarily a mast cell-driven disease. Mast cells, located in the dermis, degranulate and release pre-formed and newly synthesized mediators, leading to the characteristic wheal and flare reaction.
  • Key Mediators:
    • Histamine: The primary mediator, causes vasodilation (erythema), increased vascular permeability (wheal), and pruritus. It acts on H1 and H2 receptors.
    • Other Vasoactive Mediators: Leukotrienes (LTC4, LTD4, LTE4), prostaglandins (PGD2), platelet-activating factor (PAF), bradykinin, and various cytokines (e.g., IL-4, IL-13, TNF-α). These amplify the inflammatory response and contribute to wheal formation and pruritus.
  • Mast Cell Activation Pathways:
    • IgE-dependent: Allergen binding to specific IgE on mast cell surface, cross-linking IgE receptors (FcεRI), leading to degranulation. Common in acute allergic urticaria.
    • IgE-independent:
      • Autoimmune: Autoantibodies (IgG, IgE) directed against FcεRI on mast cells/basophils or against IgE itself. This is a common mechanism in CSU, accounting for 30-50% of cases (autoimmune urticaria). These antibodies activate mast cells directly.
      • Complement activation: Products of complement activation (e.g., C3a, C5a) can directly activate mast cells.
      • Non-specific degranulation: Direct activation by drugs (e.g., opioids, NSAIDs), physical stimuli (e.g., cold, pressure), infections, or stress.
      • Coagulation Pathway: The extrinsic coagulation pathway, particularly thrombin, has been implicated in mast cell activation and CSU severity, possibly via protease-activated receptors (PARs).
• Risk Factors:
  • Acute Urticaria:
    • Infections: Viral (e.g., common cold, hepatitis), bacterial (e.g., Streptococcus), parasitic (e.g., Giardia, Ascaris), fungal.
    • Medications: NSAIDs (aspirin, ibuprofen), antibiotics (penicillin, sulfonamides), ACE inhibitors, opioids, muscle relaxants, IV contrast media.
    • Foods: Peanuts, tree nuts, shellfish, milk, eggs, soy, wheat, food additives.
    • Insect stings/bites: Bees, wasps, ants.
    • Contactants: Latex, plants, animal dander.
  • Chronic Spontaneous Urticaria:
    • Autoimmunity: Association with autoimmune thyroid disease (Hashimoto's thyroiditis, Grave's disease), vitiligo, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus.
    • Infections: Chronic H. pylori infection (controversial), dental infections, chronic sinusitis.
    • Stress: Psychological stress can exacerbate or trigger flares.
    • Genetics: Familial predisposition is rare but exists.
  • Chronic Inducible Urticaria: Specific physical stimuli (cold, heat, pressure, sun, vibration, water) or exercise/stress (cholinergic).
• Protective Factors: None definitively established for preventing the onset of urticaria. For those with established urticaria, avoidance of known specific triggers (e.g., identified food allergens, NSAIDs if sensitive) is protective against flares. Stress management may reduce exacerbations.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Wheals (Hives): Evanescent, pruritic, well-demarcated, raised erythematous lesions with a central pallor. Size varies from pinpoint to large plaques. Key characteristic: individual lesions typically last less than 24 hours (often 30 minutes to a few hours) and leave no residual changes (pigmentation, bruising, scarring) upon resolution.
  • Pruritus: Intense itching, often worse at night. Can severely impair quality of life, sleep, and daily activities.
  • Angioedema: Swelling of deeper dermal and subcutaneous/submucosal tissues. Characterized by non-pitting, often painful or burning rather than itchy, swelling. Commonly affects the face (eyelids, lips, tongue), hands, feet, and genitalia. Can involve the gastrointestinal tract (abdominal pain, vomiting) or upper airways (laryngeal edema, stridor, dysphonia, dyspnea – a medical emergency). Angioedema can occur with or without wheals.
• Early Signs:
  • Localized itching or tingling sensation preceding the visible eruption of wheals.
  • Initial small, scattered papules that coalesce.
• Advanced Signs:
  • Widespread involvement with large, confluent plaques of urticaria.
  • Significant angioedema involving the face, lips, tongue, or pharynx, potentially causing airway compromise.
  • Associated systemic symptoms (rare in typical urticaria, more concerning for anaphylaxis or urticarial vasculitis).
• Atypical Presentations:
  • Urticarial Vasculitis: Lesions last longer than 24-48 hours, may be painful or burn, often leave a bruise-like discoloration or purpura upon resolution. May be associated with systemic symptoms (fever, arthralgia, myalgia, abdominal pain, renal or pulmonary involvement). Requires skin biopsy for diagnosis.
  • Hereditary Angioedema (HAE): Recurrent episodes of angioedema without concomitant urticaria. Often triggered by trauma, stress, or medical procedures. Due to C1 esterase inhibitor deficiency or dysfunction. Lifethreatening if airway involved.
  • Exercise-induced anaphylaxis: Urticaria/angioedema occurring exclusively during or after physical exercise, sometimes accompanied by systemic symptoms (hypotension, gastrointestinal symptoms, respiratory distress).

Physical Examination

• Inspection:
  • Wheals: Observe morphology (size, shape, distribution), color (erythematous with central pallor), and transient nature (observe individual lesions over time or ask about their duration).
  • Angioedema: Note location, extent, and appearance of swelling (non-pitting, often skin-colored or slightly erythematous).
  • Dermographism (urticaria factitia): Linear wheals that appear within minutes of firm stroking of the skin. Present in ~5% of healthy individuals and ~20-30% of CU patients.
  • Signs of specific inducible urticaria: E.g., target lesions after cold exposure (cold urticaria), pinpoint wheals with surrounding erythema (cholinergic urticaria), swelling in pressure areas (delayed pressure urticaria).
• Palpation:
  • Wheals: Feel slightly raised and warm.
  • Angioedema: Non-pitting edema, can be firm or doughy. May be tender or painful.
• Special Tests:
  • Ice Cube Test: For cold urticaria. Place an ice cube in a thin plastic bag on the forearm for 5-10 minutes. A positive test shows a localized wheal or angioedema upon rewarming.
  • Pressure Test: For delayed pressure urticaria. Apply pressure (e.g., by hanging a 1-2 kg weight on the shoulder or upper arm for 15-20 minutes, or sitting on a narrow stool for 10-15 minutes). Wheals and swelling appear 30 minutes to 12 hours later at the pressure sites.
  • Warm Water Immersion/Exercise: For cholinergic urticaria. Induce sweating by exercise or a warm bath. Small, punctate wheals surrounded by a red flare appear.
  • Light Test: For solar urticaria. Exposure to specific wavelengths of light.
  • Vibration Test: For vibratory angioedema. Apply a vibrating device to the forearm.
  • ASST (Autologous Serum Skin Test): Inject patient's own serum intradermally. A positive reaction (wheal >5 mm compared to saline control) suggests autoreactivity, often seen in autoimmune CSU. Not routinely recommended for diagnosis but can support the autoimmune etiology.

Diagnostic Approach

History Taking

• Key Questions:
  • Duration: Acute (<6 weeks) or Chronic (≥6 weeks)? Crucial for classification.
  • Frequency and Pattern: Daily, intermittent, seasonal, time of day?
  • Appearance of individual lesions: Do they last less than 24 hours? Do they leave marks? (Distinguishes from urticarial vasculitis).
  • Pruritus severity: How itchy? Does it interfere with sleep or daily activities? (Urticaria Activity Score - UAS7, a validated tool: daily sum of wheal count and itch severity over 7 days).
  • Associated symptoms: Is angioedema present? If so, location (facial, laryngeal, GI), and associated symptoms (pain, burning, dyspnea, dysphonia, abdominal pain). Are there systemic symptoms (fever, joint pain, muscle pain, weight loss)?
  • Triggers/Exacerbating factors:
    • Medications: Any new medications or changes? NSAIDs, ACE inhibitors, antibiotics are common culprits.
    • Foods: Any specific food associations? (Less common in CSU, more in acute allergic urticaria).
    • Infections: Recent viral illness, dental abscess, urinary tract infection, H. pylori?
    • Physical stimuli: Cold, heat, pressure, exercise, sun, water, vibration?
    • Contactants: Latex, plants, chemicals?
    • Stress: Emotional or physical stress.
    • Hormonal factors: Menstrual cycle, pregnancy, thyroid disorders.
    • Occupation/Hobbies: Exposure to allergens or irritants.
  • Past medical history: Atopy (asthma, allergic rhinitis), autoimmune diseases (especially thyroid), H. pylori infection, inflammatory bowel disease, malignancy (rarely).
  • Family history: Any family history of urticaria or angioedema (especially for HAE).
  • Response to previous treatments: What medications have been tried, dosages, duration, and efficacy?
• Red Flags:
  • Symptoms of Anaphylaxis: Dyspnea, stridor, wheezing, throat tightness, dysphagia, dizziness, syncope, hypotension, rapid weak pulse, severe abdominal pain, vomiting. Requires immediate emergency intervention.
  • Angioedema with airway involvement: Swelling of tongue, lips, pharynx, larynx resulting in stridor, voice changes, or difficulty breathing.
  • Lesions lasting >24-48 hours, painful/burning, and leaving residual pigmentation/purpura: Suggests urticarial vasculitis, requiring biopsy.
  • Systemic symptoms: Fever, arthralgia, significant fatigue, weight loss (suggests underlying systemic disease or urticarial vasculitis).
  • Recurrent angioedema without wheals: Raises suspicion for hereditary or acquired angioedema (C1-INH deficiency).

Laboratory Tests

Laboratory testing for urticaria should be guided by history and physical examination findings, especially for chronic urticaria. Extensive testing without specific indications is discouraged as it rarely identifies a cause for CSU and can lead to unnecessary interventions. - First-Line (For Chronic Urticaria, guided by history/PE, per EAACI/GA2LEN/EDF/WAO guidelines): * Complete Blood Count (CBC) with differential: To check for infection, eosinophilia (parasitic infection/atopy), or systemic inflammation. * Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP): Markers of inflammation; elevated in some autoimmune or inflammatory conditions, including a subset of CSU. * Thyroid Stimulating Hormone (TSH) and thyroid peroxidase (TPO) antibodies: To screen for autoimmune thyroid disease, which is commonly associated with CSU. - Confirmatory (If specific indications from history/PE): * Allergy testing (Skin prick tests or specific IgE blood tests): Only if history strongly suggests a specific IgE-mediated allergy (e.g., acute urticaria after specific food ingestion or insect sting). Rarely useful in CSU. * Autologous Serum Skin Test (ASST): Not a standard diagnostic test, but can be performed to suggest autoimmune etiology in CSU if available and clinically relevant. A positive test indicates the presence of autoantibodies (against IgE or FcεRI) capable of inducing mast cell degranulation. * Biopsy of skin lesion: Indicated if lesions persist beyond 24-48 hours, are painful/burning, or leave residual purpura/hyperpigmentation, to rule out urticarial vasculitis. Histology shows perivascular inflammatory infiltrate with evidence of leukocytoclasis and fibrin deposition in vessel walls. * C1 esterase inhibitor (C1-INH) quantitative and functional levels, C4: If hereditary or acquired angioedema is suspected (recurrent angioedema without urticaria, family history, triggers like ACE inhibitors). * Antinuclear Antibodies (ANA): If other signs of systemic lupus erythematosus or other connective tissue diseases are present. * H. pylori stool antigen or breath test: If chronic H. pylori infection is suspected, though its role in CSU is controversial. * Stool for ova and parasites: If parasitic infection is suspected (e.g., travel history, eosinophilia). - Monitoring: Laboratory tests are not typically used for routine monitoring of urticaria severity, but rather for diagnosis or assessment of medication side effects (e.g., liver/kidney function tests with cyclosporine). Clinical assessment tools like UAS7 are preferred for monitoring disease activity.

Imaging

• Recommended: Generally, imaging studies are not recommended for the routine diagnosis or evaluation of urticaria, as it is a skin condition with systemic causes rarely requiring imaging.
• Advanced: Imaging may be considered in very specific circumstances if a rare underlying cause is strongly suspected (e.g., imaging for chronic sinusitis if recurrent acute exacerbations are linked, or ultrasound/CT for suspected malignancy very rarely). However, this is guided by specific clinical findings, not routine for urticaria.

Management

Acute Management

The primary goals are symptom relief and preventing severe complications, particularly airway obstruction. - Immediate (First-hour interventions): * Identify and remove trigger: If an identifiable trigger is present (e.g., drug, food, insect sting), eliminate exposure immediately. * Systemic H1-antihistamines: Administer non-sedating H1-antihistamines (e.g., cetirizine 10 mg PO, loratadine 10 mg PO, fexofenadine 180 mg PO, desloratadine 5 mg PO) as first-line for symptomatic relief. For faster action in severe cases, intravenous diphenhydramine (25-50 mg IV) can be used, but note sedation. * Epinephrine: For signs of anaphylaxis (e.g., respiratory distress, hypotension, stridor, widespread angioedema affecting airway): * Adults: 0.3-0.5 mg of 1:1000 epinephrine intramuscularly (IM) into the mid-anterolateral thigh. Repeat every 5-15 minutes if symptoms persist. * Children: 0.01 mg/kg IM (max 0.3 mg/dose) into the mid-anterolateral thigh. * Airway assessment: Constantly monitor for signs of laryngeal edema. - Stabilization (Early management priorities): * Corticosteroids: For severe acute urticaria or angioedema not responding adequately to antihistamines, a short course of oral corticosteroids may be considered to reduce inflammation and accelerate resolution. * Dosage: Prednisone 20-50 mg PO daily for 3-7 days, then taper if symptoms allow. Avoid prolonged use due to side effects. * H2-antihistamines: Can be added to H1-antihistamines (e.g., famotidine 20 mg PO BID) for additional symptom control, though their role is less robust than H1-antihistamines. * Observation: Monitor patient closely for progression of symptoms, especially if angioedema or systemic symptoms are present. - Emergency (Crisis management): * Airway management: If laryngeal edema progresses to airway obstruction, securing the airway (e.g., endotracheal intubation, cricothyrotomy) is paramount. * Fluid resuscitation: For hypotension associated with anaphylaxis. * Oxygen supplementation: To maintain adequate oxygen saturation. * Vasopressors: If hypotension persists despite fluids and epinephrine.

Chronic Management

Management of chronic urticaria aims at achieving complete symptom control with minimal or no adverse effects, improving quality of life, and is typically a stepwise approach. - Pharmacological: * First-line: Second-generation non-sedating H1-antihistamines (e.g., bilastine, desloratadine, fexofenadine, levocetirizine, loratadine, cetirizine). * Dosage: Start with standard doses (e.g., cetirizine 10 mg daily, desloratadine 5 mg daily). * Rationale: These are effective by blocking histamine, have few sedative or anticholinergic side effects, and are safe for long-term use. * Second-line (Up-dosing antihistamines): If symptoms are not controlled after 2-4 weeks with standard doses, increase the dose of second-generation H1-antihistamines up to four-fold (e.g., cetirizine 20-40 mg daily, desloratadine 10-20 mg daily, fexofenadine 360-720 mg daily, levocetirizine 10-20 mg daily). * Rationale: Higher doses can achieve better receptor blockade and are often effective in a significant proportion of patients who do not respond to standard doses. This strategy is evidence-based and often overlooked. * Third-line (Add-on therapies): If up-dosed antihistamines fail to control symptoms after 2-4 weeks: * Omalizumab (anti-IgE monoclonal antibody): Highly effective for CSU. * Mechanism: Binds to free IgE in the circulation, reducing free IgE levels and downregulating FcεRI on mast cells and basophils, thereby reducing their excitability and mediator release. * Dosage: 300 mg subcutaneous injection every 4 weeks. (FDA approved for ages ≥12 years with CSU refractory to H1-antihistamines). * Rationale: Blocks a key pathway of mast cell activation in CSU. * Cyclosporine A (calcineurin inhibitor): For severe, refractory CSU. * Mechanism: Inhibits T-cell activation and cytokine production, also directly affects mast cell degranulation. * Dosage: 2.5-5 mg/kg/day divided into two doses. Start low (e.g., 2 mg/kg/day) and titrate up. * Monitoring: Requires close monitoring of renal function, blood pressure, and drug levels due to potential nephrotoxicity and other side effects. * Rationale: Potent immunosuppressant for severe cases, but with significant side effects. * Other pharmacological options (for refractory cases, typically by specialists): * Leukotriene Receptor Antagonists (LTRAs) (e.g., montelukast 10 mg daily, zafirlukast): May be added to antihistamines, but evidence for their efficacy in CSU is limited and inconsistent. * Systemic Corticosteroids: Short bursts (e.g., prednisone 20-50 mg/day for 3-7 days) can be used for acute exacerbations of chronic urticaria, but not for long-term control due to side effects. * Immunosuppressants: Dapsone, methotrexate, mycophenolate mofetil, tacrolimus, sulfasalazine. Used for highly refractory cases under specialist guidance, based on limited evidence. - Non-pharmacological: * Avoidance of triggers: If specific triggers are identified (e.g., NSAIDs, alcohol, specific foods in acute urticaria or specific physical stimuli in CIndU), avoidance is key. However, for CSU, specific triggers are rarely identifiable, and strict elimination diets are generally not recommended without clear evidence. * Stress management: Psychological stress can exacerbate urticaria. Relaxation techniques, mindfulness, and cognitive behavioral therapy (CBT) may be helpful. * Cool compresses/baths: Can provide symptomatic relief from pruritus. * Loose-fitting clothing: Reduces irritation. * Moisturizers: Can help with skin barrier function, though not a primary treatment. - Monitoring: * Symptom control: Regularly assess disease activity using tools like UAS7 (Urticaria Activity Score over 7 days), which measures the sum of daily wheal count (0-3) and itch severity (0-3) scores. A total score of 0-6 indicates well-controlled disease. * Quality of life (QoL): Use specific QoL questionnaires (e.g., CU-Q2oL) to assess the impact of the disease. * Adverse effects of medications: Monitor for side effects, especially with higher dose antihistamines (sedation, dry mouth), omalizumab (injection site reactions, rare anaphylaxis), and cyclosporine (renal function, blood pressure, infections, hyperkalemia).

Treatment Algorithms (Based on EAACI/GA2LEN/EDF/WAO Guidelines 2021)

The guidelines propose a stepwise approach for the management of chronic spontaneous urticaria:

• Step 1 (First-Line):

  • Recommended: Standard dose of a second-generation non-sedating H1-antihistamine daily.
  • Examples: Cetirizine 10 mg, desloratadine 5 mg, fexofenadine 180 mg, levocetirizine 5 mg, loratadine 10 mg.
  • Duration: Continue for 2-4 weeks.
  • Rationale: Safe, effective, and well-tolerated first choice.

• Step 2 (Second-Line):

  • Recommended: If symptoms are not controlled at Step 1, increase the dose of the second-generation H1-antihistamine up to four-fold.
  • Examples: Cetirizine 20-40 mg, desloratadine 10-20 mg, fexofenadine 360-720 mg, levocetirizine 10-20 mg.
  • Duration: Continue for 2-4 weeks.
  • Rationale: Many patients respond to higher doses, providing better receptor blockade without significantly increased side effects compared to adding other medications.

• Step 3 (Third-Line):

  • Recommended: If symptoms are not controlled at Step 2, add Omalizumab.
  • Dosage: Omalizumab 300 mg subcutaneous injection every 4 weeks.
  • Rationale: Omalizumab is a highly effective, targeted biologic therapy for CSU, often achieving complete control in patients refractory to high-dose antihistamines.
  • Alternative (if Omalizumab is unavailable or ineffective): Add Cyclosporine A.
    • Dosage: 2.5-5 mg/kg/day, typically initiated at a lower dose and titrated.
    • Rationale: Potent immunosuppressant, but with significant side effects and requiring careful monitoring.

• Step 4 (Fourth-Line / Refractory Cases):

  • Recommended: For patients who do not respond to Omalizumab and/or Cyclosporine A, consider other immunosuppressive agents.
  • Examples: Dapsone, methotrexate, mycophenolate mofetil, tacrolimus, sulfasalazine.
  • Rationale: These are used in highly refractory cases, based on less robust evidence and often in a specialist setting due to potential side effects. The choice depends on clinician experience and patient profile.
  • Additional considerations:
    • Short-term oral corticosteroids: Only for severe exacerbations, not for continuous use.
    • Investigational therapies: Participation in clinical trials for novel agents.
    • Multidisciplinary approach: Involvement of allergists/immunologists, dermatologists, and sometimes rheumatologists or mental health professionals.

Complications

• Common:
  • Sleep disturbance: Due to severe pruritus, leading to fatigue and impaired daily functioning.
  • Psychological distress: Anxiety, depression, and significant reduction in quality of life due to persistent symptoms, unpredictable flares, and cosmetic impact.
  • Skin excoriations: From scratching, leading to secondary infections (rare).
• Serious:
  • Airway obstruction: Due to severe angioedema involving the larynx or pharynx. This is a medical emergency requiring immediate attention and potentially intubation.
  • Anaphylaxis: While pure urticaria alone rarely causes anaphylaxis, it can be a component of a systemic anaphylactic reaction, especially when associated with angioedema, hypotension, or respiratory symptoms.
• Long-term:
  • Persistence of chronic urticaria: Can last for many years, leading to prolonged use of medications and associated side effects.
  • Medication side effects: Especially with systemic corticosteroids (weight gain, osteoporosis, diabetes), cyclosporine (nephrotoxicity, hypertension, infections), and other immunosuppressants.
  • Social and professional impact: Reduced productivity, absenteeism, and difficulty with social interactions.

Prognosis

• Factors:
  • Acute Urticaria: Generally excellent prognosis. Most cases resolve spontaneously within days to weeks.
  • Chronic Spontaneous Urticaria (CSU): Prognosis is more variable.
    • Approximately 50% achieve remission within 1 year, and up to two-thirds within 5 years. However, some cases can persist for decades.
    • Factors associated with a longer course include severe disease, presence of angioedema, positive ASST, and concomitant autoimmune diseases (e.g., autoimmune thyroiditis).
  • Chronic Inducible Urticaria (CIndU): Often persists for many years, and some forms (e.g., cold urticaria, dermographism) can be lifelong, though severity may fluctuate.
• Survival: Urticaria itself is not typically a life-threatening condition, and survival rates are excellent. However, severe angioedema with airway compromise can be fatal if not managed promptly.
• Quality of Life: Significantly impaired in patients with active chronic urticaria. The unpredictability of flares, intense pruritus, and cosmetic effects of wheals and angioedema can severely impact physical, emotional, and social well-being. Effective treatment can dramatically improve quality of life.

Prevention

• Primary (Preventing initial occurrence):
  • Avoidance of known triggers: If a specific trigger for acute urticaria is identified (e.g., certain foods, drugs like NSAIDs, insect stings), avoiding re-exposure is the primary preventive measure. However, most cases of acute urticaria are self-limited and idiopathic.
  • Addressing underlying infections: Treating chronic infections (e.g., H. pylori, dental infections) has been suggested, but evidence for preventing CSU onset is limited.
  • Stress management: Reducing psychological stress may help prevent exacerbations in susceptible individuals.
• Secondary (Early detection and intervention):
  • Prompt diagnosis: Early and accurate diagnosis of chronic urticaria allows for timely initiation of effective treatment, which can lead to better symptom control and potentially shorter disease duration.
  • Identify and manage comorbidities: Screening for and managing associated autoimmune diseases (e.g., thyroid disease) or infections may reduce disease activity.
• Tertiary (Preventing complications):
  • Patient education: Educate patients about their condition, potential triggers, recognizing signs of severe angioedema (especially airway involvement), and when to seek emergency care.
  • Action plan for angioedema: For patients with recurrent angioedema, provide an individualized action plan, including carrying an epinephrine auto-injector if there's a risk of anaphylaxis or airway compromise.
  • Regular follow-up: To monitor disease activity, adjust treatment, and manage medication side effects.
  • Psychological support: Address mental health impacts (anxiety, depression) through counseling or CBT.

Special Populations

• Pediatric:
  • Epidemiology: Acute urticaria is very common in children, often triggered by viral infections. CSU is less common than in adults.
  • Diagnosis: History taking from parents/caregivers is crucial. Physical examination similar to adults.
  • Management:
    • Antihistamines: Second-generation non-sedating H1-antihistamines are first-line. Dosages must be age- and weight-adjusted (e.g., cetirizine 5-10 mg daily depending on age, levocetirizine 2.5-5 mg daily). Up-dosing is also an option.
    • Omalizumab: Approved for CSU in children aged 12 years and older (300 mg every 4 weeks).
    • Cyclosporine: Can be used in severe, refractory cases under specialist supervision, with careful monitoring.
    • Oral corticosteroids: Short courses for severe flares, used cautiously.
• Geriatric:
  • Polypharmacy: Increased risk of drug-drug interactions. Carefully review medication list for potential triggers (e.g., NSAIDs, ACE inhibitors).
  • Comorbidities: Higher prevalence of comorbidities may impact treatment choices (e.g., renal/hepatic impairment affecting drug metabolism/excretion, cardiovascular disease).
  • Antihistamines: Non-sedating H1-antihistamines are preferred to avoid central nervous system side effects (sedation, cognitive impairment, falls) seen with first-generation agents (e.g., diphenhydramine, hydroxyzine). Start with lower doses and titrate slowly.
  • Immunosuppressants: Use with extreme caution, requiring close monitoring for side effects.
• Pregnancy:
  • Acute Urticaria: Most cases are benign and self-limited.
  • Chronic Urticaria: Can persist or worsen during pregnancy.
  • Management:
    • Non-pharmacological: Avoidance of triggers, cool baths.
    • Pharmacological:
      • First-line: Second-generation non-sedating H1-antihistamines, particularly loratadine and cetirizine, are considered low-risk during pregnancy (Category B).
      • Second-line: Other non-sedating antihistamines (e.g., desloratadine, levocetirizine) may be used if needed.
      • Oral corticosteroids: Short bursts may be used for severe flares when benefits outweigh risks (e.g., prednisone, which is mostly metabolized by the placenta, limiting fetal exposure).
      • Omalizumab: Data on use in pregnancy is limited but reassuring from registries. It should only be used if the potential benefit justifies the potential risk to the fetus.
      • Cyclosporine: Generally avoided due to potential fetal toxicity unless absolutely necessary for severe, refractory disease, with careful monitoring.
      • Breastfeeding: Loratadine and cetirizine are considered safe.
• Comorbidities:
  • Autoimmune diseases (e.g., thyroiditis, lupus): Screen for and manage these conditions, as they are often associated with CSU. The management of urticaria itself remains largely the same.
  • Anxiety/Depression: Recognize and address the psychological impact of chronic urticaria. Referral to mental health professionals for CBT or other interventions can significantly improve quality of life.
  • Angioedema: Differentiate from hereditary or acquired angioedema due to C1-INH deficiency, which requires specific treatments (e.g., C1-INH concentrate, bradykinin receptor antagonists).

Clinical Pearls

• Diagnostic:
  • "The Rule of 24 Hours": The most crucial diagnostic clue for true urticaria is that individual wheals typically resolve spontaneously within 24 hours (often much faster, within minutes to hours) and leave no residual marks. If lesions persist beyond 24-48 hours or leave behind bruising/pigmentation, consider urticarial vasculitis and perform a skin biopsy.
  • Chronic Urticaria is often idiopathic: Avoid excessive and unfocused investigations for CSU without specific clinical clues, as a specific cause is rarely found in the majority of cases (CSU). Over-testing leads to patient frustration and unnecessary costs.
  • Angioedema without wheals: Always consider hereditary or acquired angioedema, especially if there's a family history, triggers like ACE inhibitors, or recurrent episodes.
• Treatment:
  • Up-dosing is key: Do not hesitate to increase the dose of second-generation H1-antihistamines up to four-fold (e.g., cetirizine 40 mg daily) before considering other therapies. This is an evidence-based and effective strategy.
  • Omalizumab is a game-changer: For CSU patients refractory to high-dose antihistamines, omalizumab offers significant symptom control and improvement in quality of life with a favorable safety profile.
  • Short-term steroids for flares: Oral corticosteroids should be reserved for acute, severe exacerbations and used for the shortest possible duration (e.g., 3-7 days). They are not for long-term control.
• Pitfalls:
  • Over-reliance on first-generation antihistamines: While effective for acute symptom relief, their sedative and anticholinergic side effects make them unsuitable for long-term chronic urticaria management, especially in older adults or those needing to operate machinery.
  • Misdiagnosing urticarial vasculitis: Failure to recognize prolonged lesion duration, pain/burning, and residual purpura can delay diagnosis of a potentially systemic condition.
  • Unnecessary dietary restrictions: Unless a specific food allergy is clearly identified (rare in CSU), recommending broad elimination diets is generally unhelpful and can lead to nutritional deficiencies and patient frustration.
  • Ignoring psychological impact: The chronic nature and unpredictability of urticaria can have profound psychological effects. Neglecting these aspects can hinder overall patient well-being, even if symptoms are medically controlled.

Recent Updates

• Guidelines: The 2021 EAACI/GA2LEN/EDF/WAO (European Academy of Allergy and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization) Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria provides the most current, comprehensive, and evidence-based recommendations. These guidelines reinforce the stepwise approach with up-dosing antihistamines and early introduction of omalizumab.
• Evidence:
  • Continued strong evidence for the efficacy and safety of omalizumab in CSU, with ongoing research into optimal dosing strategies and predictors of response.
  • Emerging understanding of the role of the coagulation cascade and other non-histaminergic pathways in CSU pathophysiology, opening avenues for new therapeutic targets.
  • Research into novel biologics targeting other mast cell-related pathways, such as anti-FcεRI antibodies or KIT inhibitors (e.g., ligelizumab, remibrutinib), showing promise in clinical trials for refractory CSU.
• Controversies:
  • Role of Helicobacter pylori eradication: While some studies suggest a link between H. pylori and CSU, the evidence for routine eradication to treat CSU is conflicting and not generally recommended.
  • Dietary interventions for CSU: Despite patient belief, there is limited high-quality evidence to support specific diets (e.g., pseudoallergen-free diet) for routine CSU management outside of very specific, rarely identified true food allergies.
  • Autologous serum therapy (AST): While historically used in some centers, its efficacy is not consistently proven, and it is not recommended by major guidelines due to lack of strong evidence and practical limitations.

Key References

• Guidelines:
  • Zuberbier T, et al. The international EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2022;77(3):734-766. (Updated version of the 2021 guidelines)
  • Joint Task Force on Practice Parameters, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277.
• Studies:
  • Maurer M, et al. Omalizumab for the treatment of chronic idiopathic urticaria. N Engl J Med. 2013;368(10):924-935. (Key study demonstrating omalizumab efficacy)
  • Sussman G, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria in children and adolescents. J Allergy Clin Immunol. 2018;141(3):1038-1045.
• Reviews:
  • Powell RJ, et al. BSACI guidelines for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565.
  • Church MK, et al. The role of histamine H1-receptors and their antagonists in chronic urticaria. J Allergy Clin Immunol Pract. 2016;4(4):613-620.